Abstract |
This double-blind, vehicle-controlled, multicenter study evaluated the efficacy and safety of a new topical antineoplastic agent, masoprocol, in the treatment of actinic keratoses of the head and neck. Of the 113 patients who applied topical masoprocol twice a day for 14 to 28 days, there was a mean decrease in actinic keratoses from 15.0 to 5.4 and a median percent reduction from baseline actinic keratosis count of 71.4% at the 1-month follow-up visit. Comparable numbers for the vehicle-treated group were 13.4 to 11.1 actinic keratoses and 4.3% median percent reduction. Irritation, as manifested by erythema or flaking, occurred in 61.5% of topical masoprocol-treated patients versus 26.7% of those treated with vehicle and did not correlate with clinical response. Topical masoprocol appears to be useful in the treatment of actinic keratoses.
|
Authors | E A Olsen, M L Abernethy, C Kulp-Shorten, J P Callen, S D Glazer, A Huntley, M McCray, A B Monroe, E Tschen, J E Wolf Jr |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 24
Issue 5 Pt 1
Pg. 738-43
(May 1991)
ISSN: 0190-9622 [Print] United States |
PMID | 1869646
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Administration, Cutaneous
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Clinical Protocols
- Double-Blind Method
- Facial Dermatoses
(drug therapy, pathology)
- Female
- Head
- Humans
- Keratosis
(drug therapy, pathology)
- Male
- Masoprocol
(administration & dosage, adverse effects, therapeutic use)
- Middle Aged
- Ointments
|